| dc.contributor.author | Linch, M | |
| dc.contributor.author | Attard, G | |
| dc.date.accessioned | 2018-02-16T15:50:10Z | |
| dc.date.issued | 2018-02 | |
| dc.identifier.citation | Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 29 (2), pp. 290 - 292 | |
| dc.identifier.issn | 0923-7534 | |
| dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/1232 | |
| dc.identifier.eissn | 1569-8041 | |
| dc.identifier.doi | 10.1093/annonc/mdx785 | |
| dc.format | Print | |
| dc.format.extent | 290 - 292 | |
| dc.language | eng | |
| dc.language.iso | eng | |
| dc.subject | Humans | |
| dc.subject | Androstenes | |
| dc.subject | Prednisone | |
| dc.subject | Prospective Studies | |
| dc.subject | Cell Cycle | |
| dc.subject | Cell Proliferation | |
| dc.subject | Male | |
| dc.subject | Genome-Wide Association Study | |
| dc.subject | Wnt Signaling Pathway | |
| dc.subject | Prostatic Neoplasms, Castration-Resistant | |
| dc.subject | Abiraterone Acetate | |
| dc.title | Prostate cancers that 'Wnt' respond to abiraterone. | |
| dc.type | Journal Article | |
| rioxxterms.versionofrecord | 10.1093/annonc/mdx785 | |
| rioxxterms.licenseref.startdate | 2018-02 | |
| rioxxterms.type | Journal Article/Review | |
| dc.relation.isPartOf | Annals of oncology : official journal of the European Society for Medical Oncology | |
| pubs.issue | 2 | |
| pubs.notes | Not known | |
| pubs.organisational-group | /ICR | |
| pubs.organisational-group | /ICR/Primary Group | |
| pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
| pubs.organisational-group | /ICR | |
| pubs.organisational-group | /ICR/Primary Group | |
| pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
| pubs.publication-status | Published | |
| pubs.volume | 29 | |
| pubs.embargo.terms | Not known | |
| dc.contributor.icrauthor | Marsden, | en |
